- Home
- IMRN vs ACXP Comparison
IMRN vs ACXP Comparison
Compare IMRN & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- ACXP
- Stock Information
- Founded
- IMRN 1994
- ACXP 2017
- Country
- IMRN Australia
- ACXP United States
- Employees
- IMRN N/A
- ACXP N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- ACXP Health Care
- Exchange
- IMRN Nasdaq
- ACXP Nasdaq
- Market Cap
- IMRN 9.2M
- ACXP 8.4M
- IPO Year
- IMRN N/A
- ACXP 2021
- Fundamental
- Price
- IMRN $1.88
- ACXP $0.43
- Analyst Decision
- IMRN Strong Buy
- ACXP Strong Buy
- Analyst Count
- IMRN 1
- ACXP 2
- Target Price
- IMRN $5.00
- ACXP $10.00
- AVG Volume (30 Days)
- IMRN 25.2K
- ACXP 18.4M
- Earning Date
- IMRN 07-07-2025
- ACXP 08-08-2025
- Dividend Yield
- IMRN N/A
- ACXP N/A
- EPS Growth
- IMRN N/A
- ACXP N/A
- EPS
- IMRN N/A
- ACXP N/A
- Revenue
- IMRN $4,048,286.00
- ACXP N/A
- Revenue This Year
- IMRN N/A
- ACXP N/A
- Revenue Next Year
- IMRN N/A
- ACXP N/A
- P/E Ratio
- IMRN N/A
- ACXP N/A
- Revenue Growth
- IMRN 82.90
- ACXP N/A
- 52 Week Low
- IMRN $1.50
- ACXP $0.30
- 52 Week High
- IMRN $2.87
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- IMRN 58.70
- ACXP 47.99
- Support Level
- IMRN $1.68
- ACXP $0.52
- Resistance Level
- IMRN $1.94
- ACXP $0.63
- Average True Range (ATR)
- IMRN 0.09
- ACXP 0.09
- MACD
- IMRN 0.02
- ACXP 0.00
- Stochastic Oscillator
- IMRN 76.92
- ACXP 17.33
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.